Junshi’s COVID Antiviral Superior To Paxlovid? Some Caveats Unveiled

 
• By Dexter Jie Yan

Unexpected protocol changes and a single-blind design for a Phase III head-to-head trial seem to have played to the advantage of Junshi’s oral derivative of Gilead’s antiviral remdesivir in COVID-19.

clinical trial progress
Junshi's claim of antiviral win over Paxlovid in head-to-head trial seems on shaky ground • Source: Alamy

More from China

More from Focus On Asia